G1 Therapeutics, Inc.
GTHXHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $82.5M | $51.3M | $31.5M | $45.3M | — | — |
| Operating income | −$39.5M | −$136.2M | −$142.5M | −$96.5M | −$129.0M | −$89.3M |
| Net income | −$48.0M | −$147.6M | −$148.4M | −$99.3M | −$122.4M | −$85.3M |
| Total assets | $121.5M | $188.0M | $254.1M | $228.6M | $284.8M | $371.3M |
| Total liabilities | $86.2M | $119.2M | $110.6M | $51.2M | $29.3M | $12.4M |
| Equity | $35.4M | $68.7M | $143.5M | $177.4M | $255.5M | $358.8M |
| EPS (diluted) | $-0.93 | $-3.38 | $-3.54 | $-2.62 | — | — |
| Shares out. | 51.7M | 42.7M | 42.0M | 37.6M | 37.4M | 28.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −47.9%
- Net margin
- −58.1%
- Return on equity
- −135.6%
- Return on assets
- −39.5%
- Return on capital (ROCE)
- −43.0%
- Liabilities / assets
- 70.9%
- Debt / equity
- 2.43×
- Book value / share
- $0.69
- Revenue growth (YoY)
- 60.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -18.07distress
- Accruals / assets
- −7.9%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventSep 18, 2024
- Results of operationsAug 8, 2024
- Entered a material agreement · Director / officer change · Other material eventAug 7, 2024
- Regulation FD disclosureJun 24, 2024
- Shareholder voteJun 14, 2024
- Results of operationsMay 1, 2024
- Director / officer changeMar 22, 2024
- Results of operationsFeb 28, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.